Tris-HCl（三羟甲基氨基甲烷盐酸盐）是一种广泛使用的缓冲剂，其在中性至弱碱性条件下（pH 7.0–9.0）具有稳定的缓冲能力。20 mmol/L浓度和pH 7.8的配制参数使其适用于多种科研场景，尤其在分子生物学、生物化学和细胞学研究中具有重要价值。 · DNA/RNA稳定性与 ...

它们能够稳定溶液的pH值，为生物分子提供一个适宜的微环境，从而确保实验的准确性和可靠性。其中，Tris-HCl（三羟甲基氨基甲烷盐酸盐）缓冲液因其适宜的pKa值、良好的缓冲性能和广泛的应用范围而备受青睐。然而，Tris-HCl缓冲液的一个显著特性是其温度敏感 ...

GAS2 is a cytoskeletal regulator that interacts with both F-actin and microtubules. Here, cryo-EM structures of GAS2 domains ...

Multi-epitope immunopurifications of huntingtin (HTT) from vulnerable brain regions of Huntington’s disease (HD) models ...

Bonus Dec 05, 2019 Dec 07, 2019 Oct 23, 2019 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Mar 19, 2015 Mar 20, 2015 Jan 30, 2015 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Mar 15, ...

This important study shows that the Nora virus, a natural Drosophila pathogen that also persistently infects many laboratory fly stocks, infects intestinal stem cells (ISCs), leading to a shorter life ...

We lysed cells in IPH buffer (1 ml; 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 0.1 mM PMSF) at 4 °C for 30 min and removed debris by centrifugation. The cleared lysate was then ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data needed to take the pain relief drug to the FDA this year. The latest ...

The HCL journey has been relentless, gratifying and marked with a series of achievements. Our unified efforts have catapulted the company from a garage start-up to a conglomerate whose businesses span ...

A New Jersey-based drug company believes it has enough evidence to seek approval for an experimental, first-of-its-kind pain medication. On Thursday, Tris Pharma released data from a clinical trial of ...

Mr Nadar passed the reins to his daughter, Roshni in July 2020. In a strategic succession plan, HCL Group Founder Shiv Nadar has gifted 47% of his stake in HCL Corp and Vama Sundari Investments ...

Tris Pharma has announced positive data from two Phase III trials of cebranopadol, as well as positive data from a human abuse potential (HAP) study to compare the therapy against various opioids.